Metraipolis › archive › dc_5c96cb4f247d

Gut microbiota modulation in GLP-1RA and SGLT-2i therapy: clinical implications and mechanistic insights in type 2 diabetes — Europe PMC PMID:41409228

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41409228
DOI
10.1093/ckj/sfaf351
License (as archived)
solo-consultazione
Archived
2026-11-08T13:36:59.666Z
SHA-256 of the archived text
2078f8a9fab0fb45e35e2995beacddc30f1cabdf0517ec84a8d5b40e233847a1
Stable URL of this page
https://metraipolis.com/documento/dc_5c96cb4f247d

How to cite

Gut microbiota modulation in GLP-1RA and SGLT-2i therapy: clinical implications and mechanistic insights in type 2 diabetes — Europe PMC PMID:41409228 — Europe PMC (en), https://europepmc.org/article/MED/41409228 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5c96cb4f247d (Metraipolis archive dc_5c96cb4f247d, sha256 2078f8a9fab0fb45e35e2995beacddc30f1cabdf0517ec84a8d5b40e233847a1)
BibTeX
@misc{dc5c96cb4f247d,
  title = {Gut microbiota modulation in GLP-1RA and SGLT-2i therapy: clinical implications and mechanistic insights in type 2 diabetes — Europe PMC PMID:41409228},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41409228},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5c96cb4f247d; sha256 2078f8a9fab0fb45e35e2995beacddc30f1cabdf0517ec84a8d5b40e233847a1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41409228. Agents can read the archived copy with the MCP tool read_document.